Breaking News

BioElpida Completes Next Phase of BVX-0918 GMP Production

BioVaxys’ Vaccine for the treatment of platinum-resistant ovarian cancer achieved positive immunological & clinical results in human trials.

Author Image

By: Charlie Sternberg

Associate Editor

BioVaxys Technology Corp.’s Lyon, France-based bioproduction partner, BioElpida, has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys’ vaccine for treatment of platinum-resistant ovarian cancer. About the OVCAR-3 Cell Line The OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccine. This assay is required by regulator...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters